News
Zoetis (ZTS) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
Zoetis (NYSE: ZTS)Q2 2024 Earnings CallAug 06, 2024, 8:00 a.m. ET
Operator
Source Fool.com
Why Zoetis Stock Was Moving Higher Tuesday
Shares of Zoetis (NYSE: ZTS), the leading animal pharmaceutical maker, were climbing today after the company reported better-than-expected results in its second-quarter earnings report and raised
3 Unstoppable Dividend Stocks Yielding More Than 4% for Income-Seeking Investors to Buy in August and Hold Forever
The past week has been a rotten one for most portfolios. On Monday, Aug. 5, the benchmark S&P 500 index began the trading session about 3% lower. That led the benchmark index to a loss of about 9.4%
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Except for the last several days, the past 12 months have been pretty good for stocks across the board and especially successful for Vertex Pharmaceuticals (NASDAQ: VRTX). Shares of the biotech
Prediction: These Could Be the Best-Performing Growth Stocks Through 2030
When it comes to investing in the right companies for your portfolio, you need to ensure you select businesses that you understand and have the competitive advantages, financials, and leadership to
Is Regeneron Pharmaceuticals Due for a Stock Split?
Regeneron Pharmaceuticals (NASDAQ: REGN) stock is trading above the $1,000 mark. It's at a high enough threshold that the company could decide to split its stock. That would lower the share price
2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off
There are plenty of excellent reasons to invest in dividend stocks, including the fact that only rock-solid companies can afford to sustain payout increases for a long time. When you put your money
Prediction: 2 Stocks That Will Be Worth More Than Johnson & Johnson 10 Years From Now
Few healthcare companies are more famous than Johnson & Johnson (NYSE: JNJ). The pharmaceutical giant earned its stature in the industry thanks to its incredible innovative abilities and a business
Is This Decision by Pfizer Bad News for Eli Lilly?
Eli Lilly (NYSE: LLY) stock has soared by double digits over the past year -- and for good reason. The pharma giant sells two of the most sought-after drugs today, weight loss treatments Mounjaro
Prediction: This Could Be Amgen's Next Massive Growth Opportunity
The biotech Amgen (NASDAQ: AMGN) isn't exactly known as a growth stock. Over the past few years, the company's organic revenue hasn't been increasing at a particularly impressive rate. The drugmaker
Should Investors Worry About Vertex Pharmaceuticals $3.6 Billion Q2 Loss? Not Even for a Second.
Vertex Pharmaceuticals (NASDAQ: VRTX) has churned out nice profits quarter after quarter for years. The big biopharmaceutical company's cystic fibrosis (CF) franchise made it easy.
However, Vertex
Forget Johnson & Johnson: Another Healthcare Giant Is a Much Better Bet for Growth
Johnson & Johnson (NYSE: JNJ) is one of the top healthcare companies in the world. Last year, it spun off its consumer health business to focus on growing other parts of its operations, which
Is Pfizer Winning Its $43 Billion Bet?
Pfizer (NYSE: PFE) is one of the most successful pharmaceutical companies ever. In 2022, it brought in more than $100 billion in revenue -- a record for itself and for the entire industry. Of
Vertex Pharmaceuticals (VRTX) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
Vertex Pharmaceuticals (NASDAQ: VRTX)Q2 2024 Earnings CallAug 01, 2024, 4:30 p.m. ET
Operator
Source Fool.com
Biogen (BIIB) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
Biogen (NASDAQ: BIIB)Q2 2024 Earnings CallAug 01, 2024, 8:30 a.m. ET
Operator
Source Fool.com
Got $500? 2 Compelling Growth Stocks to Buy and Hold Forever
Great companies can deliver meaningful portfolio growth in a wide range of economic and market environments. From established companies to emerging businesses, the types of stocks you favor will
Pfizer Just Confirmed It's a Dividend Investor's Dream Stock
Pfizer (NYSE: PFE) has been a nightmare for many investors in recent years. At one point earlier this year, the big pharma stock was nearly 60% below its peak set in late 2021.
However, the
Pfizer to Buy a GLP-1 Drugmaker? Here's Why You Shouldn't Count on That Happening
The anti-obesity drug market could be worth a staggering $100 billion, according to some analysts. That's a huge growth opportunity, and it's a reason why many top drugmakers in the world are
Pfizer Just Did This for the First Time in 6 Quarters. Time to Buy?
Just a couple of years ago, Pfizer's (NYSE: PFE) revenue was soaring thanks to sales of its coronavirus vaccine. In fact, the vaccine became the world's best-selling pharmaceutical product and even
Pfizer (PFE) Q2 2024 Earnings Call Transcript
Image source: The Motley Fool.
Pfizer (NYSE: PFE)Q2 2024 Earnings CallJul 30, 2024, 10:30 a.m. ET
Operator
Source Fool.com
Prediction: This Will Be Pfizer's Next Big Move
Despite its impressive performance in 2020 and 2021, it's no secret that Pfizer (NYSE: PFE) is in the process of reinventing itself. Without much of the windfall from its coronavirus products
Europe Just Turned Down Biogen's Alzheimer's Drug. Is the Stock One to Avoid, or a Bad News Buy?
Biogen (NASDAQ: BIIB) built itself into a multiple sclerosis (MS) treatment giant over the years -- but as older blockbusters lost exclusivity, growth stalled. And last year, annual revenue dropped
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
According to some research, bull markets tend to last an average of 2.6 years. The one we are currently experiencing has been going on for almost two years -- maybe it will soon end, maybe it won't
Better Buy: Abbott Laboratories vs. Intuitive Surgical
Investors looking for stocks that can go up want to turn their heads toward the medical technology industry. Demand for devices that enable minimally invasive surgical procedures and remote
Why AbbVie Stock Was Cruising Higher on Thursday
AbbVie (NYSE: ABBV) stock was the cure for what ails a portfolio on Thursday. The sturdy pharmaceutical company was a favorite of investors, who were trading its shares up by nearly 4% in price in